Proteomics International Laboratories Ltd. (AU:PIQ) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Proteomics International Laboratories Ltd has ended its exclusive licensing agreement with Sonic Healthcare USA for the PromarkerD test, freeing the company to pursue alternative licensing avenues and direct-to-consumer strategies in the US market. The PromarkerD test, which can predict kidney disease in diabetics, is expected to have a significant health impact for over 32 million Americans living with diabetes. Preparations for the launch include establishing the test in a third-party CLIA certified US lab, with commercial availability anticipated in FY25.
For further insights into AU:PIQ stock, check out TipRanks’ Stock Analysis page.